Hybrid optimization based on non-coplanar needles for brachytherapy dose planning.
Conclusions: The hybrid inverse optimization method achieved high conformity in the clinical practice. The non-coplanar needle can help to achieve a better dose distribution than the coplanar needle. PMID: 31435434 [PubMed]
Conclusions: We found that the use of the hybrid applicator allowed for adequate target coverage in a patient with unusual anatomy. The patient tolerated treatment well and demonstrated favorable response on follow-up exam and imaging. The long-term curative result needs to be further evaluated. PMID: 31435436 [PubMed]
Conditions: Prostate Cancer; Non-metastatic Prostate Cancer; Prostate Adenocarcinoma Interventions: Procedure: Radical therapy (radiotherapy or prostatectomy [radiotherapy can be external beam or brachytherapy]; Procedure: Focal therapy; Procedure: Focal therapy after Finasteride 5Mg tablets for 12 weeks; Procedure: Focal therapy after Bicalutamide 50Mg tablets for 12 weeks Sponsors: Imperial College London; Prostate Cancer UK; Imperial Clinical Trials Unit (ICTU) Not yet recruiting
CONCLUSION: IBT is an overall safe procedure, which facilitates high rates of local tumor control in treatment of metastatic gastric adenocarcinoma. Compared to surgical metastasectomy, similar overall survival rates could be achieved in our patient collective after IBT application. PMID: 31348004 [PubMed - as supplied by publisher]
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
The primary goal of this study is to estimate the rate of treatment related late GI/GU toxicity. It was originally reported in 2010. This is a report of long-term patient outcome following treatment with external beam radiation therapy (EBRT) and prostate high dose rate (HDR) brachytherapy from a prospective phase II, multi-institutional collaborative trial conducted by NRG Oncology/RTOG.
Authors: Yilmaz E, Gurocak S, Melekoglu R, Koleli I, Faydali S, Temelli O, Yar T Abstract BACKGROUND This retrospective clinical study aimed to investigate the effect of prognostic factors and adjuvant radiotherapy in patients with high-grade early-stage endometrial cancer on overall survival (OS) and disease-free survival (DFS). MATERIAL AND METHODS The medical records of patients diagnosed with high-grade, early stage (I or II) endometrial adenocarcinoma who had received adjuvant radiotherapy after surgery were reviewed. RESULTS Seventy-nine patients included 39 patients (49.4%) with stage II endometrial cancer, ...
An 83 year-old male with Gleason score 4+3 prostatic adenocarcinoma status post brachytherapy developed obstructive voiding symptoms nine years after brachytherapy. PSA was 0.67. Cystoscopy noted multiple papillary urethral tumors concerning for primary urethral carcinoma. Immunophenotype of biopsies supported diagnosis of Gleason score 4+4 prostatic adenocarcinoma. Androgen deprivation therapy was started. Cystoscopy performed four years later, for microhematuria workup, noted complete resolution of the urethral tumors.
Introduction: Endometrial cancer is the first pelvic gynecological cancer in terms of incidence in France and is represented in 80% by type 1 histological (endometrioid adenocarcinoma). In January 2016, The European Society of Medical Oncology, European Society of Gynaecological Oncology and European SocieTy of Radiotherapy and Oncology (ESMO-ESGO-ESTRO) published a new postoperative classification, based on definitive pathological analysis, aimed for adapting adjuvant management.